Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMK0NGB)

Drug Name

Rozanolixizumab Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Generalized myasthenia gravis	8C60	Approved	[1]
Myasthenia gravis	8C6Y	Phase 2	[2]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Immunoglobulin Fc receptor (FCR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nipocalimab	DM0622O	Myasthenia gravis	8C6Y	Phase 3	[3]
DX-2500	DM3BWTM	Ischemic heart disease	BA40-BA6Z	Investigative	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Immunoglobulin Fc receptor (FCR)	TTPY4SE	NOUNIPROTAC	Antagonist	[2]

------------------------------------------------------------------------------------

References

1	FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761286
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals. Drugs. 2022 Jun;82(8):865-887.
4	Fully Human Monoclonal Antibody Inhibitors of the Neonatal Fc Receptor Reduce Circulating IgG in Non-Human Primates. Front Immunol. 2015; 6: 176.